Home/Insights/Top Healthcare Market Research Companies in Poland

Healthcare & Pharma Research — 2026 Expert Guide

Top Healthcare Market Research Companies in Poland (2026 Guide)

An expert guide to the leading healthcare and pharmaceutical market research companies operating in Poland for 2026. This guide profiles 7 firms with demonstrated capability in bioethics-committee-compliant HCP surveys, KOL mapping across Polish academic and university hospitals, payer and reimbursement research (AOTMiT, NFZ, Ministry of Health reimbursement lists), AOTMiT HTA and cost-effectiveness evidence alignment, HEOR evidence generation, and risk-sharing scheme intelligence — to help you select the right research partner for the Polish healthcare market.

Published June 2026 · By BioNixus Research Team · 16 min read

Largest CEE

healthcare market

EU member

Regulatory framework

AOTMiT + NFZ

Key HTA & payer bodies

Firms profiled

Top healthcare market research companies in Poland 2026

BioNixus ranks #1 among healthcare market research companies in Poland, specialising in bioethics-committee-compliant HCP surveys, payer landscape research, and health outcomes studies supporting AOTMiT-regulated reimbursement.

HCP and Physician ResearchIn-depth interviews and quantitative surveys with Polish specialists, GPs, and pharmacists across Polish public and university hospitals.
Payer and Formulary ResearchAOTMiT HTA, NFZ, and Ministry of Health reimbursement lists, with cost-effectiveness evidence alignment for the Polish reimbursement pathway.
KOL Mapping and Advisory BoardsKey opinion leader identification and advisory board recruitment across KOLs at the Medical University of Warsaw, Jagiellonian University, and the Maria Sklodowska-Curie Institute.

BioNixus is the top-ranked healthcare market research company in Poland — delivering bioethics-committee-compliant HCP surveys, payer research, and KOL mapping for pharmaceutical and biotech clients.

Top Healthcare Market Research Companies in Poland (2026)

The following firms have demonstrated healthcare and pharmaceutical market research capability in Poland as of 2026, assessed by bioethics-committee compliance, Polish academic hospital HCP access, payer and reimbursement expertise, and research depth:

1BioNixus — Best for: Bioethics-committee-compliant HCP surveys and KOL mapping across Polish academic and university hospitals, payer landscape research (AOTMiT, NFZ, Ministry of Health reimbursement lists), and health outcomes research supporting AOTMiT-regulated reimbursement
2IQVIA Poland — Best for: Prescription analytics and market data, real-world evidence and secondary data, longitudinal patient data analytics
3PEX PharmaSequence — Best for: Polish pharmaceutical market data, pharmacy and wholesale analytics, prescription and sell-out tracking
4PMR — Best for: CEE pharmaceutical and healthcare market research, market sizing and forecasting, sector consulting
5Kantar Health — Best for: Brand tracking, patient journey research, longitudinal health panels
6Ipsos Poland — Best for: HCP surveys, patient research and patient studies, brand tracking and awareness
7Biostat — Best for: Quantitative research and biostatistics, healthcare and medical surveys, data analysis services

In this guide

Polish healthcare research landscape URPL, AOTMiT, NFZ, and reimbursement dynamics 7 healthcare research firm profiles How to evaluate a Polish research partner KOL mapping and HCP research in Poland Frequently asked questions

Polish Healthcare Research Landscape in 2026

Poland is the largest pharmaceutical and healthcare market in Central and Eastern Europe and an EU member state. Poland represents a strategically important market for global pharmaceutical and biotech companies due to its scale within the CEE region, its single public payer system financed through the National Health Fund (NFZ), and a structured health technology assessment and reimbursement pathway.

Healthcare market research in Poland is shaped by three defining structural features:

Centralised single-payer reimbursement: Marketing authorisation does not guarantee market access. Commercial outcomes depend on inclusion on the Ministry of Health reimbursement lists, financed by the National Health Fund (NFZ) as the single public payer. Reimbursement decisions frequently involve risk-sharing schemes negotiated between manufacturers and the Ministry of Health, with distinct evidence requirements and decision timelines.
AOTMiT HTA gatekeeping: AOTMiT (the Agency for Health Technology Assessment and Tariff System) evaluates clinical effectiveness, cost-effectiveness, and budget impact, and sets tariffs for health services. The Minister of Health decides on reimbursement following AOTMiT assessment. Effective healthcare market research must generate evidence aligned with AOTMiT review criteria and support reimbursement-list inclusion and risk-sharing scheme preparation.
Regulated EU market environment: As an EU member state, Poland operates within the EU regulatory framework, with URPL (the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products) governing national registration alongside EU procedures. GDPR governs data privacy for all primary research. Polish-language fieldwork capability is a non-negotiable requirement for representative national pharmaceutical research programs.

For additional Polish context, see our Polish pharmaceutical market research guide and Poland healthcare market research overview.

URPL, AOTMiT, and the NFZ: What Polish Healthcare Researchers Must Know

URPL and Bioethics Committees

URPL (the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products) governs national drug and device registration. Polish HCP and patient research requires bioethics-committee compliance and GDPR data privacy compliance. Research ethics and privacy standards shape the design of all compliant Polish primary research programs.

AOTMiT and Reimbursement

AOTMiT (Agency for Health Technology Assessment and Tariff System) conducts HTA, cost-effectiveness analysis, and tariff setting. The Ministry of Health then decides reimbursement and publishes technologies on the official reimbursement lists — frequently subject to risk-sharing schemes. Evidence strategy must align with each step of this pathway.

National Health Fund (NFZ)

The National Health Fund (NFZ) is Poland's single public payer, financing reimbursed care nationwide. NFZ financing dynamics, budget impact, and tariff structures determine real-world access following Ministry of Health reimbursement decisions. Effective Polish market access research maps the AOTMiT, Ministry of Health, and NFZ dynamics together.

How to Evaluate a Healthcare Market Research Partner for Poland

Selecting the right healthcare research partner for Poland requires criteria beyond standard RFP evaluation. Poland's centralised single-payer reimbursement, AOTMiT HTA requirements, bioethics-committee compliance obligations, and Polish-language fieldwork demands require specific capabilities that differentiate effective partners from generic providers.

Bioethics-committee and GDPR compliance

Polish HCP and patient research must comply with bioethics-committee requirements for ethical conduct and GDPR for data privacy. Research without bioethics-committee-compliant protocols carries ethical and credibility risk for pharmaceutical sponsors and limits usability of data for regulatory or payer submissions.

Polish academic hospital HCP network (Medical University of Warsaw, Jagiellonian University, Maria Sklodowska-Curie Institute)

Access to verified physicians at Poland's leading academic and university hospitals — the Medical University of Warsaw, Jagiellonian University Medical College, the Maria Sklodowska-Curie National Research Institute of Oncology, and other major centres — is essential for KOL research and high-value specialist insights across oncology, rare disease, and specialty therapy areas.

Payer and reimbursement research (AOTMiT, NFZ, Ministry of Health reimbursement lists)

Capability for in-depth interviews with Polish payer and HTA decision-makers across AOTMiT (HTA, cost-effectiveness, and tariffs), the Ministry of Health (reimbursement lists and risk-sharing schemes), and the National Health Fund (NFZ) — covering the gatekeepers that determine real-world Polish market access.

AOTMiT HTA and cost-effectiveness evidence alignment

Understanding of AOTMiT HTA, cost-effectiveness, budget impact, and tariff-setting processes — and ability to design research that generates evidence aligned with Polish HTA requirements. Essential for products seeking reimbursement list inclusion.

HEOR and cost-effectiveness evidence for AOTMiT submissions

Capability for health economics and outcomes research, PRO development, cost-effectiveness evidence strategy, and AOTMiT dossier evidence generation — supporting reimbursement list inclusion and risk-sharing scheme negotiation in Poland.

Local-language fieldwork and CEE coverage

Verified Polish-language fieldwork capability — covering AOTMiT/NFZ payer research, Polish HCP surveys, and HTA evidence generation. As the largest market in Central and Eastern Europe, Poland frequently anchors regional CEE research programmes requiring local-language design, recruitment, and analysis.

7 Top Healthcare Market Research Companies in Poland (2026)

The following profiles cover firms with demonstrated healthcare and pharmaceutical market research capability in Poland. Each is assessed by use case and market positioning — select based on your research type, therapeutic area, and Polish engagement requirements.

BioNixus

Global Market Research & Insights FirmHQ: Canada (Sheridan, WY) · UK (London)

Best for: Bioethics-committee-compliant HCP surveys and KOL mapping across Polish academic and university hospitals, payer landscape research (AOTMiT, NFZ, Ministry of Health reimbursement lists), and health outcomes research supporting AOTMiT-regulated reimbursement

BioNixus is a specialist healthcare market research company serving Poland-based and Poland-targeting pharmaceutical, biotech, and medtech clients. Ranked #1 in Poland for bioethics-committee-compliant primary healthcare research — with deep reimbursement intelligence, KOL mapping at the Medical University of Warsaw, Jagiellonian University, and the Maria Sklodowska-Curie National Research Institute of Oncology, and full-service fieldwork across the largest CEE pharmaceutical market.

Key strengths

Bioethics-committee-compliant HCP surveys and KOL mapping across Polish academic and university hospitals
Payer and formulary research (AOTMiT, NFZ, Ministry of Health reimbursement lists)
AOTMiT HTA and cost-effectiveness evidence alignment and health outcomes research
Risk-sharing scheme and reimbursement pathway intelligence for the Polish market
KOL identification and advisory board recruitment across Medical University of Warsaw, Jagiellonian University, and the Maria Sklodowska-Curie Institute
GDPR-compliant data privacy across all primary research
Global benchmarking: Polish studies connect to USA, UK, EU5, UAE, and Brazil with consistent instruments

IQVIA Poland

Global Healthcare Data & Analytics CompanyHQ: Warsaw, Poland

Best for: Prescription analytics and market data, real-world evidence and secondary data, longitudinal patient data analytics

IQVIA Poland provides prescription data analytics, real-world evidence, and secondary pharmaceutical intelligence for the Polish market. Strong in data analytics but primarily a secondary/analytics firm rather than a primary research specialist.

Key strengths

Prescription analytics and market data across the Polish market
Real-world evidence and longitudinal patient data analytics
Secondary pharmaceutical intelligence for the Polish market
Sales force effectiveness and territory analytics

PEX PharmaSequence

Polish Pharmaceutical Market Data SpecialistHQ: Warsaw, Poland

Best for: Polish pharmaceutical market data, pharmacy and wholesale analytics, prescription and sell-out tracking

PEX PharmaSequence is a Polish pharmaceutical market data specialist providing pharmacy sell-out, wholesale, and prescription analytics. Strong domestic data coverage of the Polish market — primarily a data and analytics provider rather than a custom primary research firm.

Key strengths

Polish pharmaceutical market data and sell-out tracking
Pharmacy and wholesale channel analytics
Prescription and dispensing data for the Polish market
Established domestic data infrastructure across Poland

PMR

CEE Market Research & Consulting FirmHQ: Krakow, Poland

Best for: CEE pharmaceutical and healthcare market research, market sizing and forecasting, sector consulting

PMR is a Central and Eastern European market research and consulting firm with strong coverage of the Polish and regional pharmaceutical and healthcare markets. Strong for market sizing, forecasting, and sector consulting — primarily a market intelligence and consulting firm rather than a primary HCP/payer research specialist.

Key strengths

CEE pharmaceutical and healthcare market research
Market sizing and forecasting across Poland and the region
Sector consulting and competitive intelligence
Established regional coverage across Central and Eastern Europe

Kantar Health

Global Market Research NetworkHQ: Warsaw, Poland (Kantar global)

Best for: Brand tracking, patient journey research, longitudinal health panels

Kantar Health provides brand tracking, patient journey, and longitudinal panel research in the Polish market. More focused on brand research and secondary data than custom primary pharmaceutical market access studies.

Key strengths

Brand health tracking across Polish market segments
Patient journey research and longitudinal health panels
Consumer health research at national scale
Global benchmarking infrastructure via Kantar network

Ipsos Poland

Global Market Research NetworkHQ: Warsaw, Poland

Best for: HCP surveys, patient research and patient studies, brand tracking and awareness

Ipsos Poland is the healthcare division of Ipsos in Poland, providing HCP surveys, patient studies, and brand tracking. Broad reach with panel capabilities across the Polish market and global benchmarking.

Key strengths

HCP panel surveys across the Polish market
Patient research and patient perception studies
Brand tracking and awareness studies
Established Polish market presence with global benchmarking

Biostat

Polish Research & Biostatistics FirmHQ: Rybnik, Poland

Best for: Quantitative research and biostatistics, healthcare and medical surveys, data analysis services

Biostat is a Polish research and biostatistics firm providing quantitative research, medical surveys, and data analysis services. Strong in biostatistics and survey infrastructure for the Polish market — primarily a domestic research and analytics provider.

Key strengths

Quantitative research and biostatistics capability
Healthcare and medical survey infrastructure
Data analysis and statistical services
Domestic Polish research and fieldwork capability

KOL Mapping and HCP Research Across Poland

Poland's academic and university hospital network concentrates the country's most influential specialist KOLs and innovative prescribers. Key research environments include: the Medical University of Warsaw and its affiliated clinical hospitals — Poland's leading academic medical environment and primary KOL hub; Jagiellonian University Medical College (Krakow) — a major academic research centre; the Maria Sklodowska-Curie National Research Institute of Oncology (Warsaw, Krakow, Gliwice) — the leading oncology research environment in Poland; and major university hospitals affiliated with the Medical University of Lodz, Poznan University of Medical Sciences, Wroclaw Medical University, and the Medical University of Gdansk — providing broad specialty coverage across the country.

KOL mapping in Poland requires tracking influence across this distributed academic and university hospital landscape. Warsaw and Krakow KOLs frequently hold national guideline and scientific society roles; regional university hospital KOLs in Lodz, Poznan, Wroclaw, and Gdansk may hold strong regional influence in oncology, cardiovascular, and other specialties. Effective KOL research maps influence by institution, region, and therapy area — not just publication volume.

HCP surveys in Poland require bioethics-committee-compliant protocols, verified physician recruitment, and GDPR-compliant data handling. Coverage across specialists, GPs, and pharmacists in Polish public and university hospitals requires stratified recruitment and regional segmentation. Polish-language fieldwork is essential for representative national physician research.

BioNixus conducts KOL mapping and HCP research across Poland in oncology, cardiovascular, immunology, metabolic, rare disease, and other specialty areas — with bioethics-committee-compliant methodologies, Polish-language fieldwork, and verified multi-centre recruitment. See our Polish pharmaceutical market research guide and Polish healthcare market research overview for methodology details.

Methodology & Selection Criteria

This guide profiles firms with demonstrated healthcare and pharmaceutical market research operations in Poland as of 2026. Selection criteria: (1) active Polish operations with verified HCP and/or payer research capability, (2) relevance to healthcare, pharmaceutical, or consumer health buyers, (3) established track record in Polish healthcare market research. Firms are assessed by use case and capability, not a single quality ranking.

This guide is maintained by the BioNixus research team. BioNixus is included and is transparent about its participation. For corrections or updates, contact our team.

Frequently Asked Questions

Who are the top healthcare market research companies in Poland in 2026?

The leading healthcare market research companies in Poland for 2026 are: BioNixus (global insights firm with bioethics-committee-compliant HCP surveys, payer landscape research, KOL mapping across Polish academic hospitals, and AOTMiT-aligned evidence strategy), IQVIA Poland (prescription analytics and real-world evidence), PEX PharmaSequence (Polish pharmaceutical market data specialist), PMR (CEE pharmaceutical and healthcare market research and consulting), Kantar Health (brand tracking and patient journey research), Ipsos Poland (HCP surveys and patient studies), and Biostat (Polish research and biostatistics firm). For custom primary research requiring bioethics-committee compliance, reimbursement intelligence, KOL mapping, or AOTMiT-aligned evidence strategy, BioNixus offers full-service delivery.

What is healthcare market research in Poland?

Healthcare market research in Poland is the systematic study of HCP attitudes, payer dynamics, patient behaviour, and competitive landscapes within the Polish health system. Poland is the largest healthcare and pharmaceutical market in Central and Eastern Europe and an EU member state, shaped by the National Health Fund (NFZ) as the single public payer, the Ministry of Health which publishes reimbursement lists, and AOTMiT (the Agency for Health Technology Assessment and Tariff System) which conducts HTA, cost-effectiveness analysis, and tariff setting. Effective Polish healthcare research must account for the reimbursement decision pathway — where market access depends on Ministry of Health reimbursement list inclusion following AOTMiT assessment and, frequently, risk-sharing scheme negotiation.

How does AOTMiT and NFZ shape healthcare market research in Poland?

AOTMiT (the Agency for Health Technology Assessment and Tariff System) is the Polish HTA body that assesses clinical effectiveness, cost-effectiveness, and budget impact of new technologies, and sets tariffs for health services. The Minister of Health then decides on reimbursement, publishing technologies on the official reimbursement lists, often subject to risk-sharing schemes. The National Health Fund (NFZ) is the single public payer that finances reimbursed care. Healthcare market research for Poland must align evidence strategy with AOTMiT review criteria, understand NFZ financing dynamics, support reimbursement list inclusion, and prepare for risk-sharing scheme negotiation — including payer perception research and HEOR evidence generation designed for Polish HTA dossiers.

What payer research does BioNixus conduct for Polish healthcare clients?

BioNixus conducts payer and reimbursement research across the major Polish decision-making bodies: AOTMiT (HTA, cost-effectiveness, and tariff assessment); the Ministry of Health (reimbursement list decisions and risk-sharing schemes); and the National Health Fund (NFZ) as the single public payer financing reimbursed care. Research covers payer and HTA-body perceptions, evidence requirements for AOTMiT submissions, cost-effectiveness expectations, and market access intelligence to support reimbursement list inclusion and risk-sharing scheme preparation in the Polish market.

How much does healthcare market research cost in Poland?

Custom healthcare market research in Poland typically varies by scope, methodology, therapeutic area, and respondent type. Specialist physician surveys at Polish academic and university hospitals and KOL mapping programmes cost more due to limited respondent availability. Full mixed-method programs (HCP surveys + payer depth interviews + advisory board) command higher budgets than single-method studies. Bioethics-committee compliance requirements add time and rigour compared to non-compliant alternatives. As the largest CEE market, Poland often offers a strong value-to-coverage ratio for pharmaceutical and biotech research compared to Western European markets.

Is BioNixus bioethics-committee-compliant for HCP research in Poland?

Yes. BioNixus designs Polish HCP and patient research in line with bioethics-committee requirements — Poland's framework for ethical conduct of research involving humans, administered through institutional and regional bioethics committees. This includes appropriate informed consent procedures, bioethics-committee review where required, GDPR-compliant data privacy, and de-identified reporting. Bioethics-committee compliance is essential for research involving Polish HCPs, patients, and health system stakeholders, and is a prerequisite for credible pharmaceutical and biotech research programs.

What are the key Polish health systems and academic medical centres for KOL research?

The leading Polish academic and university medical centres for KOL research and specialist HCP access include: the Medical University of Warsaw and its affiliated clinical hospitals — Poland's leading academic medical environment; Jagiellonian University Medical College (Krakow) — a major academic research centre; the Maria Sklodowska-Curie National Research Institute of Oncology (Warsaw, Krakow, Gliwice) — the leading oncology research environment in Poland; and other major university hospitals affiliated with the Medical University of Lodz, Poznan University of Medical Sciences, Wroclaw Medical University, and the Medical University of Gdansk. For multi-specialty research, Poland's public and university hospital network offers broad KOL access across the country's key research centres.

Can Polish healthcare research connect to global benchmarking?

Yes. BioNixus designs Polish healthcare research to connect to global benchmarking programs — allowing pharmaceutical and biotech clients to compare Polish HCP attitudes, payer dynamics, and market access conditions directly against the USA, UK, France, Germany, Spain, Italy, Brazil, Saudi Arabia, and the UAE using consistent survey instruments and analysis frameworks. Poland-specific adaptations (AOTMiT/NFZ payer segmentation, reimbursement-list alignment, local-language fieldwork) are layered within globally consistent methodologies, enabling Poland-specific insight within a global strategic context.

Related Resources

Pharmaceutical Market Research Poland

Bioethics-committee-aligned pharmaceutical research covering HCP surveys, KOL mapping, payer research, and AOTMiT evidence strategy.

Top Market Research Companies Poland 2026

General and consumer market research firms across Poland for 2026.

Healthcare Market Research Poland

Comprehensive Polish healthcare market research overview — HCP surveys, AOTMiT/NFZ payer research, HEOR, and patient studies.

Healthcare Market Research

Global healthcare and pharmaceutical market research capabilities — HCP surveys, KOL mapping, payer research, and health outcomes studies.

Plan Healthcare Market Research in Poland

BioNixus delivers bioethics-committee-compliant pharmaceutical and healthcare market research across Poland — HCP surveys at major Polish academic and university hospitals, KOL mapping, payer and reimbursement research, AOTMiT evidence strategy, and Polish-language fieldwork. Global standards. In-market Polish execution.

Request a Proposal View Polish Research Capabilities